Therapeutic potential of peroxynitrite decomposition catalysts: A patent review

Lauren M. Slosky, Todd W Vanderah

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Introduction: Peroxynitrite is a cytotoxic oxidant species implicated in a host of pathologies, including inflammatory and neurodegenerative diseases, cancer, radiation injury and chronic pain. With the recognition of the role of peroxynitrite in disease, numerous experimental and therapeutic tools have arisen to probe peroxyntirite's pathophysiological contribution and attenuate its oxidative damage. Peroxynitrite decomposition catalysts (PNDCs) are redox-active compounds that detoxify peroxynitrite by catalyzing its isomerization or reduction to nitrate or nitrite.Areas covered: This review discusses recent research articles and patents published 1995 - 2014 on the development and therapeutic use of PNDCs. Iron and manganese metalloporphyrin PNDCs attenuate the toxic effects of peroxynitrite and are currently being developed for clinical applications. Additionally, some Mn porphyrin-based PNDCs have optimized pharmaceutical properties such that they exhibit greater peroxynitrite selectivity. Other classes of PNDC agents, including bis(hydroxyphenyl)dipyrromethenes and metallocorroles, have demonstrated preclinical efficacy, oral availability and reduced toxicity risk.Expert opinion: Interest in the drug-like properties of peroxynitrite-neutralizing agents has grown with the realization that PNDCs will be powerful tools in the treatment of disease. The design of compounds with enhanced oral availability and peroxynitrite selectivity is a critical step toward the availability of safe, effective and selective redox modulators for the treatment of peroxynitrite-associated pathologies.

Original languageEnglish (US)
Pages (from-to)443-466
Number of pages24
JournalExpert Opinion on Therapeutic Patents
Volume25
Issue number4
DOIs
StatePublished - 2015

Fingerprint

Peroxynitrous Acid
Therapeutics
Oxidation-Reduction
Metalloporphyrins
Pathology
Radiation Injuries
Patents
Poisons
Porphyrins
Expert Testimony
Therapeutic Uses
Manganese
Nitrites
Oxidants
Chronic Pain
Neurodegenerative Diseases
Pharmaceutical Preparations
Nitrates

Keywords

  • Cancer/radiation
  • Cardiovascular
  • CNS
  • Diabetes
  • Inflammatory
  • Peroxynitrite
  • Sepsis
  • Superoxide
  • Superoxide dismutase mimic
  • Transplant

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Therapeutic potential of peroxynitrite decomposition catalysts : A patent review. / Slosky, Lauren M.; Vanderah, Todd W.

In: Expert Opinion on Therapeutic Patents, Vol. 25, No. 4, 2015, p. 443-466.

Research output: Contribution to journalArticle

@article{8ed3509c2dab4f5797f74d5cb1f3f6c4,
title = "Therapeutic potential of peroxynitrite decomposition catalysts: A patent review",
abstract = "Introduction: Peroxynitrite is a cytotoxic oxidant species implicated in a host of pathologies, including inflammatory and neurodegenerative diseases, cancer, radiation injury and chronic pain. With the recognition of the role of peroxynitrite in disease, numerous experimental and therapeutic tools have arisen to probe peroxyntirite's pathophysiological contribution and attenuate its oxidative damage. Peroxynitrite decomposition catalysts (PNDCs) are redox-active compounds that detoxify peroxynitrite by catalyzing its isomerization or reduction to nitrate or nitrite.Areas covered: This review discusses recent research articles and patents published 1995 - 2014 on the development and therapeutic use of PNDCs. Iron and manganese metalloporphyrin PNDCs attenuate the toxic effects of peroxynitrite and are currently being developed for clinical applications. Additionally, some Mn porphyrin-based PNDCs have optimized pharmaceutical properties such that they exhibit greater peroxynitrite selectivity. Other classes of PNDC agents, including bis(hydroxyphenyl)dipyrromethenes and metallocorroles, have demonstrated preclinical efficacy, oral availability and reduced toxicity risk.Expert opinion: Interest in the drug-like properties of peroxynitrite-neutralizing agents has grown with the realization that PNDCs will be powerful tools in the treatment of disease. The design of compounds with enhanced oral availability and peroxynitrite selectivity is a critical step toward the availability of safe, effective and selective redox modulators for the treatment of peroxynitrite-associated pathologies.",
keywords = "Cancer/radiation, Cardiovascular, CNS, Diabetes, Inflammatory, Peroxynitrite, Sepsis, Superoxide, Superoxide dismutase mimic, Transplant",
author = "Slosky, {Lauren M.} and Vanderah, {Todd W}",
year = "2015",
doi = "10.1517/13543776.2014.1000862",
language = "English (US)",
volume = "25",
pages = "443--466",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Therapeutic potential of peroxynitrite decomposition catalysts

T2 - A patent review

AU - Slosky, Lauren M.

AU - Vanderah, Todd W

PY - 2015

Y1 - 2015

N2 - Introduction: Peroxynitrite is a cytotoxic oxidant species implicated in a host of pathologies, including inflammatory and neurodegenerative diseases, cancer, radiation injury and chronic pain. With the recognition of the role of peroxynitrite in disease, numerous experimental and therapeutic tools have arisen to probe peroxyntirite's pathophysiological contribution and attenuate its oxidative damage. Peroxynitrite decomposition catalysts (PNDCs) are redox-active compounds that detoxify peroxynitrite by catalyzing its isomerization or reduction to nitrate or nitrite.Areas covered: This review discusses recent research articles and patents published 1995 - 2014 on the development and therapeutic use of PNDCs. Iron and manganese metalloporphyrin PNDCs attenuate the toxic effects of peroxynitrite and are currently being developed for clinical applications. Additionally, some Mn porphyrin-based PNDCs have optimized pharmaceutical properties such that they exhibit greater peroxynitrite selectivity. Other classes of PNDC agents, including bis(hydroxyphenyl)dipyrromethenes and metallocorroles, have demonstrated preclinical efficacy, oral availability and reduced toxicity risk.Expert opinion: Interest in the drug-like properties of peroxynitrite-neutralizing agents has grown with the realization that PNDCs will be powerful tools in the treatment of disease. The design of compounds with enhanced oral availability and peroxynitrite selectivity is a critical step toward the availability of safe, effective and selective redox modulators for the treatment of peroxynitrite-associated pathologies.

AB - Introduction: Peroxynitrite is a cytotoxic oxidant species implicated in a host of pathologies, including inflammatory and neurodegenerative diseases, cancer, radiation injury and chronic pain. With the recognition of the role of peroxynitrite in disease, numerous experimental and therapeutic tools have arisen to probe peroxyntirite's pathophysiological contribution and attenuate its oxidative damage. Peroxynitrite decomposition catalysts (PNDCs) are redox-active compounds that detoxify peroxynitrite by catalyzing its isomerization or reduction to nitrate or nitrite.Areas covered: This review discusses recent research articles and patents published 1995 - 2014 on the development and therapeutic use of PNDCs. Iron and manganese metalloporphyrin PNDCs attenuate the toxic effects of peroxynitrite and are currently being developed for clinical applications. Additionally, some Mn porphyrin-based PNDCs have optimized pharmaceutical properties such that they exhibit greater peroxynitrite selectivity. Other classes of PNDC agents, including bis(hydroxyphenyl)dipyrromethenes and metallocorroles, have demonstrated preclinical efficacy, oral availability and reduced toxicity risk.Expert opinion: Interest in the drug-like properties of peroxynitrite-neutralizing agents has grown with the realization that PNDCs will be powerful tools in the treatment of disease. The design of compounds with enhanced oral availability and peroxynitrite selectivity is a critical step toward the availability of safe, effective and selective redox modulators for the treatment of peroxynitrite-associated pathologies.

KW - Cancer/radiation

KW - Cardiovascular

KW - CNS

KW - Diabetes

KW - Inflammatory

KW - Peroxynitrite

KW - Sepsis

KW - Superoxide

KW - Superoxide dismutase mimic

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=84924979111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924979111&partnerID=8YFLogxK

U2 - 10.1517/13543776.2014.1000862

DO - 10.1517/13543776.2014.1000862

M3 - Article

C2 - 25576197

AN - SCOPUS:84924979111

VL - 25

SP - 443

EP - 466

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 4

ER -